Pre type 1 autoimmune diabetes presenting as childhood stress hyperglycaemia

dinesha, siddhartha

doi:10.26226/morressier.5d9b6231ea541d6ca8493efe

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from these efforts, a very limited number of related compounds have been prepared and reported which, however, have either shown no activity at all, being far less active than their precursors [139], or they display IC 50 values over 40 µM against tested cell lines [140], or, in some cases, their activities are not reported at all, presumably due to the lack of it [141]. Nevertheless, compound 63 ( Figure 22) incorporating a structurally interesting imidazoquinonyl moiety has shown low cytotoxicity against HeLa cancer cells (IC 50 = 15.1 µM), slightly higher than its chalcone precursor or N-phenyl pyrazoline analogue [142]. The activity decreased significantly when the authors replaced the methoxy group of the C-5 phenyl ring with a nitro or chloride substituent or when they left the ring unsubstituted.…”

Section: Imidazole and Benzimidazole Pyrazoline Hybridsmentioning

confidence: 99%

“…The activity decreased significantly when the authors replaced the methoxy group of the C-5 phenyl ring with a nitro or chloride substituent or when they left the ring unsubstituted. or N-phenyl pyrazoline analogue [142]. The activity decreased significantly when the authors replaced the methoxy group of the C-5 phenyl ring with a nitro or chloride substituent or when they left the ring unsubstituted.…”

Section: Imidazole and Benzimidazole Pyrazoline Hybridsmentioning

confidence: 99%

See 1 more Smart Citation

Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview

Matiadis

Sagnou

2020

IJMS

View full text Add to dashboard Cite

Pyrazolines are five-membered heterocycles possessing two adjacent nitrogens. They have attracted significant attention from organic and medicinal chemists due to their potent biological activities and the numerous possibilities for structural diversification. In the last decade, they have been intensively studied as targets for potential anticancer therapeutics, producing a steady yearly rise in the number of published research articles. Many pyrazoline derivatives have shown remarkable cytotoxic activities in the form of heterocyclic or non-heterocyclic based hybrids, such as with coumarins, triazoles, and steroids. The enormous amount of related literature in the last 5 years prompted us to collect all these published data from screening against cancer cell lines, or protein targets like EGFR and structure activity relationship studies. Therefore, in the present review, a comprehensive account of the compounds containing the pyrazoline nucleus will be provided. The chemical groups and the structural modifications responsible for the activity will be highlighted. Moreover, emphasis will be given on recent examples from the literature and on the work of research groups that have played a key role in the development of this field.

show abstract